Resource Summary

Clinical Question:
Is tiotropium useful as add-on therapy in asthmatic patients who are poorly controlled on an Inhaled Corticosteroid (ICS) or ICS + Long-Acting Beta Agonist (LABA)?

Bottom-line:
In moderate-severe asthma^ uncontrolled on ICS or ICS+LABA^ the addition of Tiotropium prevents exacerbations for one in 18-36 patients over 4-52 weeks. Much of the research is at high risk of bias and changes in other surrogate outcomes (like FEV1) are of uncertain clinical importance.


*** Original Documents can be found and downloaded using the link provided below ***

https://www.acfp.ca/tools-for-practice/

Publication Date: 2015-12-7
Last Updated on PCR: 2017-03-31 16:47:52